Information Provided By:
Fly News Breaks for March 7, 2018
RIGL
Mar 7, 2018 | 10:54 EDT
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating and $7 price target on Rigel Pharmaceuticals shares despite the company reporting Q4 EPS 5c below the firm's estimates, as Pantginis believes the key focus for the stock is the April 17 PDUFA date for Tavalisse, which he expects to have a positive outcome. He noted another April catalyst for the company as well, the Phase 2 results for fostamatinib in the treatment of IgA Nephropathy.
News For RIGL From the Last 2 Days
There are no results for your query RIGL